Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: A meta-analysis

Annals of Surgical Oncology

Volumn 20, Issue 7, 2013, Pages 2419-2427

  Zhang, Shui Shen ^a,b   Huang, Qing Yuan ^a,b   Yang, Hong ^a,b   Xie, Xuan ^a,b   Luo, Kong Jia ^a,b   Wen, Jing ^a,b   Cai, Xiao Li ^c   Yang, Fu ^a,b   Hu, Yi ^a,b   Fu, Jian Hua ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Guangdong Esophageal Cancer Research Institute   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER CHEMOTHERAPY; CHEMORADIOTHERAPY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; HUMAN; META ANALYSIS; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84878875938     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2859-4     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-52. (Pubitemid 37485141)
3. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681-92.
4. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84.
5. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet Oncol. 2002;359:1727-33. (Pubitemid 34607086)
6. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330-7. (Pubitemid 46207006)
7. Brucher BL, Stein HJ, Zimmerman F, Werner M, Sarbia M, Busch R, et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol. 2004;30:963-71. (Pubitemid 39462527)
8. Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, et al. Biomarkers of response to therapy in oesophago-gastric cancer. Gut. 2009;58:127-43.
9. Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, et al. p53 mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol. 2010;17:804-11.
10. Lam KY. Tsao SW, Zahng D, Law S, He D, Ma L, et al. Prevalence and predictive value of p53 mutation in patients with esophageal squamous cell carcinomas: prospective clinico-pathological study and survival analysis of 70 patients. Int J Cancer. 1997;74:212-9. (Pubitemid 27234513)
11. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;37:413-31.
12. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807-10. (Pubitemid 24359290)
13. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-67. (Pubitemid 23289454)
14. Levine AJ. p53, cellular gatekeeper for growth and division. Cell. 1997;88:323-31. (Pubitemid 27131374)
15. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 1998;292:435-45. (Pubitemid 28282455)
16. Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, et al. p53 mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol. 2009;17:804-11.
17. Yamasaki M, Miyata H, Fujiwara Y, Takiguchi S, Nakajima K, Nishida T, et al. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2010;17:634-42.
18. Okumura H, Natsugoe S, Matsumoto M, Mataki Y, Takatori H, Ishigami S, et al. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer. 2005;92:284-9. (Pubitemid 40343142)
19. Yang B, Rice TW, Adelstein DJ, Rybicki LA, Goldblum JR. Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma. Mod Pathol. 1999;12:251-6. (Pubitemid 29133845)
20. Sunada F, Itabashi M, Ohkura H, Okumura T. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. World J Gastroenterol. 2005;11:5696-700. (Pubitemid 41684927)
21. Yamamoto Y, Yamai H, Seike J, Yoshida T, Takechi H, Furukita Y, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Ann Surg Oncol. 2012;19:757-65.
22. Kishi K, Doki Y, Yano M, Yasuda T, Fujiwara Y, Takiguchi S, et al. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers. Clin Cancer Res. 2003;9:4368-75. (Pubitemid 37248393)
23. Fukuchi M, Fukai Y, Sohda M, Miyazaki T, Nakajima M, Inose T, et al. Expression of the prolyl isomerase Pin1 is a useful indicator of sensitivity to chemoradiotherapy in advanced esophageal squamous cell carcinoma. Oncology Rep. 2009;21:853-9.
24. Nam TK, Lee JH, Cho SH, Chung IJ, Ahn SJ, Song JY, et al. Low hMLH1 expression prior to definitive chemoradiotherapy predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Lett. 2008;260:109-17.
25. Sarbia M, Ott N, Pühringer-Oppermann F, Brücher BLDM. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer. 2007;97:1404-8. (Pubitemid 350114789)
26. Sohda M, Ishikawa H, Masuda N, Kato H, Miyazaki T, Nakajima M, et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer. 2004;110:838-44. (Pubitemid 38758509)
27. Pakos EE, Kyzas PA, Ioannidis JP. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clin Cancer Res. 2004;10:6208-14. (Pubitemid 39287528)
28. Hall PA, Lane DP. P53 in tumour pathology: can we trust immunohistochemistry? J Pathol. 1994;172:1-4. (Pubitemid 24074994)
29. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6:50-6. (Pubitemid 30064975)
30. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233-40. (Pubitemid 33741898)
31. Japanese Society for Esophageal Diseases. Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus. 9th ed. Tokyo: Kanehara & Co, Ltd; 1999.
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
33. Puglisi F, Di Loreto C, Panizzo R, Avellini C, Fongione S, Cacitti V, et al. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for ESCC. J Clin Pathol. 1996;49:456-9.
34. Muro K, Ohtsu A, Boku N, Chin K, Oda Y, Fujii T, et al. Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. Jpn J Clin Oncol. 1996;26:65-9. (Pubitemid 126467436)
35. Krasna MJ, Mao YS, Sonett JR, Tamura G, Jones R, Suntharalingam M, et al. P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. Ann Thorac Surg. 1999;68:2021-5. (Pubitemid 30027818)
36. Samejima R, Kitajima Y, Yunotani S, Miyazaki K. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res. 1999;19:5515-21. (Pubitemid 30093319)
37. Shimada Y, Watanabe G, Yamasaki S, Maeda M, Kawabe A, Kaganoi JI, et al. Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation. Eur J Cancer. 2000;36:987-93. (Pubitemid 30316423)
38. Szumilo J, Chibowski D, D browski A. Assessment of the predictive value of clinical and histopathological factors as well as the immunoexpression of p53 and bcl-2 proteins in response to preoperative chemotherapy. Dis Esophagus. 2000;13:191-7. (Pubitemid 32111838)
39. Takeno S, Noguchi T, Takahashi, Kikuchi R, Uchida Y, Yokoyama S. Immunohistochemical and clinicopathologic analysis of response to neoadjuvant therapy for esophageal squamous cell carcinoma. Dis Esophagus. 2001;14:149-54. (Pubitemid 32951987)
40. Ito T, Kaneko K, Makino R, Ito H, Konishi K, Kurahashi T, et al. Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol. 2001;36:303-11. (Pubitemid 32515076)
41. Kajiyama Y, Hattori K, Tomita N, Amano T, Iwanuma Y, Narumi K, et al. Histopathologic effects of neoadjuvant therapies for advanced squamous cell carcinoma of the esophagus multivariate analysis of predictive factors and p53 overexpression. Dis Esophagus. 2002;15:61-6. (Pubitemid 34812001)
42. Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, Nabeya Y, et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer. 2002;86:552-7. (Pubitemid 34185091)
43. Michel P, Magois K, Robert V, Chiron A, Lepessot F, Bodenant C, et al. Prognostic value of TP53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinomas treated by definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2002;54:379-85. (Pubitemid 35286801)
44. Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ, Clark GW. Apoptotic and proliferative indexes in esophageal cancer predictors of response to neoadjuvant therapy. J Gastrointest Surg. 2003;7:77-87. (Pubitemid 36875804)
45. Takeuchi H, Ozawa S, Ando N, Kitagawa Y, Ueda M, Kitajima M. Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2003;10:792-800. (Pubitemid 40486880)
46. Heeren PA, Kloppenberg FW, Hollema H, Mulder NH, Nap RE, Plukker JT. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res. 2004;24:2579-83. (Pubitemid 39166351)
47. Nakamura T, Hayashi K, Ota, M, Ide H, Takasaki K, Mitsuhashi M. Expression of p21 predicts response and survival of esophageal cancer patients treated by chemoradiotherapy. Dis Esophagus. 2004;17:315-21. (Pubitemid 40123808)
48. Miyazaki T, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, et al. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. Anticancer Res. 2005;25:2749-55.
49. Ishida M, Morita M, Saeki H, Ohga T, Sadanaga N, Watanabe M, et al. Expression of p53 and p21 and the clinical response for hyperthermochemoradiotherapy in patients with squamous cell carcinoma of the esophagus. Anticancer Res. 2007;27:3501-6. (Pubitemid 47607493)
50. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296-9. (Pubitemid 27220766)
51. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. Cancer. 2001;91:2165-74.
52. Nasierowska-Guttmejer A, Szawlowski AW, Falkowski S, Morysinski T. Histopathological evaluation of response to pre-operative concurrent chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus. Dis Esophagus. 1995;8:136-41.